Merz Pharma: Xeomin® (incobotulinumtoxinA) Receives European Approval for Treatment of Chronic Sialorrhea in Adults
Merz, a global leader in neurotoxin therapy, announced today the European approval of Xeomin® (incobotulinumtoxinA) for the symptomatic treatment of chronic sialorrhea (drooling) due to neurological disorders in adult patients.1 Xeomin® is the first and only neurotoxin with this approved indication in the EU, which follows the US FDA approval in July 2018.2
“At Merz, we are committed to bringing more good days to patients living with severe neurological disorders,” stated Stefan Brinkmann, Managing Director and Region Head EMEA at Merz. “We are confident that this new treatment option can help improve quality of life for sialorrhea patients, as well as for their relatives and caregivers. In many European countries, an approved medication for sialorrhea treatment in adults has not been available before now.”
Sialorrhea is a common but undertreated symptom accompanying neurological conditions such as Parkinson's disease, acquired brain injury, amyotrophic lateral sclerosis (ALS), cerebral palsy (CP) or stroke. Patients who experience sialorrhea suffer from a negative impact on activities of daily living, as well as social stigma and impaired quality of life. Left untreated, sialorrhea could be associated with perioral skin breakdown and pain around the mouth, choking, speech disorder, dehydration and aspiration pneumonia.3
Xeomin® is the first and only neurotoxin with this approved indication in the EU. This is the fourth therapeutic indication for Xeomin®, which was first introduced in 2005 in Germany and was approved in 13 EU member states in 2007 for the treatment of cervical dystonia and blepharospasm in adult patients. In 2009, Xeomin® received approval for the treatment of upper limb spasticity in adult patients. Xeomin® is approved in 31 EU/EEA member states for the treatment of different neurological indications and is registered in more than 60 countries worldwide.
About the SIAXI Study
The approval of Xeomin® for adult patients with sialorrhea by European authorities is based on a Phase III, randomized, double-blind, placebo-controlled, multicenter 184 patient trial. Both co-primary endpoints were successfully achieved. A statistically significant improvement was observed in change in unstimulated salivary flow rate (uSFR) and Global Impression of Change Scale (GICS), both at week four as compared to baseline pre-injection for subjects administered 100 U incobotulinumtoxinA vs. placebo (p=0.004 and p=0.002, respectively). GICS is a commonly used rating system for treatments of neurological disorders by clinicians. Overall frequency of adverse events was similar between placebo and treatment groups with no new or unexpected adverse events reported. Subjects enrolled in the study received placebo (n=36), incobotulinumtoxinA 75 U (n=74), or incobotulinumtoxinA 100 U (n=74). More detailed information about the study results can be found here.
About Xeomin ® (incobotulinumtoxinA)
Xeomin® (incobotulinumtoxinA) is a purified neurotoxin type A (150kD) free from complexing proteins that prevents the release of the neurotransmitter acetylcholine from nerve endings at muscles and salivary glands. This prescription medicine is used intramuscularly to treat increased muscle stiffness, e.g. in the arm or shoulder of adults with upper limb spasticity, or abnormal head position that happens with cervical dystonia (spasmodic torticollis) in adults, and to treat abnormal spasm of the eyelids (blepharospasm). The mode of action is similar in salivary glands by reducing saliva production after injection thereby reducing the frequency and severity of sialorrhea. IncobotulinumtoxinA is a highly potent active ingredient. Safety instructions, warnings and typical side effects for this agent should be taken into consideration.1
Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately-held for more than 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetics products across the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2017/18, Merz generated revenue of EUR 1.024,4 million; the company has a total workforce of 3,151 employees worldwide and a direct presence in 28 countries. More information is available at www.merz.com.
Copyright © 2019 Merz Pharma GmbH & Co. KGaA. All rights reserved. MERZ and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KgaA.
1 Product information Xeomin, May 2019
2 US Prescribing Information Xeomin, May 2019
3 McGeachan AJ et al. Pract Neurol 2017, 17:96-103
Merz Pharma GmbH & Co. KGaA
Mariana Smith Bourland
Phone: +49 151 4249 1466
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
REPLY: New Tool “China Beats” Provides Deep Insights Into the Chinese Market24.6.2019 09:15:00 CEST | Pressemelding
TD Reply, the company specializing in marketing and innovation consulting within the Reply Group, developed China Beats, a business intelligence solution that enables companies to gain an in-depth understanding of the Chinese market and its players. This is ensured by AI-supported social listening with connection to all major Chinese e-commerce, social media and search platforms such as Alibaba, Baidu, WeChat and Weibo. The prosperity of the Chinese population is growing at a rapid pace. According to analysts estimates, around 550 million Chinese will belong to the middle class by 2022. As a result, the Chinese market is also becoming increasingly important for international companies. Entering the market, however, is challenging, especially in terms of reliable identification of target groups, analysis of their consumer behavior and preferences. Digital data can provide a remedy, because the majority of Chinese consumers are netizens who shop on digital platforms, exchange their opini
MYbank Works With Financial Institution Partners to Serve Over 15 Million SMEs24.6.2019 05:42:00 CEST | Pressemelding
MYbank, a leading online private commercial bank in China with a focus on SME financing, today announced that the bank’s Star Plan has enabled MYbank, with its financial institution partners, to serve over 15 million small and micro enterprises (SMEs). SMEs are key drivers of economic growth and this partnership is now serving more SMEs than any other in the world. The announcement comes on the day that MYbank celebrates its 4th Anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190623005055/en/ MYbank’s 310 lending model enables inclusive finance for SMEs in China (Photo: Business Wire) MYbank’s Star Plan was announced on June 21, 2018 with the aim of using technology to enable 1,000 financial institution partners to provide more cost-effective financing services to 30 million SMEs in China within a three-year period. A little over a year later and the Star Plan is showing significant progress. As of June 2019, lev
CORRECTING and REPLACING Cooper & Turner Announces Exclusivity for Potential Combination with Beck Industries21.6.2019 19:51:00 CEST | Pressemelding
Please replace the release dated June 19, 2019, with the following corrected version due to changes to the headline and first sentence of release. The corrected release reads: COOPER & TURNER ANNOUNCES EXCLUSIVITY FOR POTENTIAL COMBINATION WITH BECK INDUSTRIES Andaray (Holdings) Limited and its direct and indirect subsidiaries (“Cooper & Turner”) have entered into an exclusivity agreement with Beck Industries (“Beck”) for potential combination of the two groups. The contemplated combined entity aims to be the first truly global manufacturer of safety critical fasteners, together supporting a broader range of industries – including renewable energy, tunneling, construction, rail, heavy equipment, downstream oil & gas, power generation and nuclear, among others. Headquartered in Sheffield, England, Cooper & Turner serves a global customer base with manufacturing and distribution operations across the European Union, China and North America. This worldwide network enables Cooper & Turner
Maor raises close to 100M$ for its first fund MAOR 121.6.2019 08:00:00 CEST | Pressemelding
Maor GP, a Luxembourg based co-investment fund dedicated to Israeli-related technology, is proud to announce the final closing of its first fund, Maor 1, at its target close to 100M$. Maor 1 is the first Luxembourg-based Israeli tech fund created to facilitate access of European investors and in particular European Family offices to the Israeli Technology ecosystem and opportunities. Rothschild & Co is a cornerstone investor in the fund comprising mainly European Family offices. Maor is a Hebrew name and our free translation of it is Explorer. Maor’s mission is to explore and invest in the leading technology ecosystem of Israel while bridging the gap between Europe and Israel. With a very strong local team in Israel and a very strong corporate network in Europe, Maor can directly source the best Israeli startups and help them grow in Europe, find partners, clients or acquisition targets and eventually create value for our investors. We, at Maor thank all our Limited Partners for their
Aqua Comms Expands Presence to Interxion’s Copenhagen Campus21.6.2019 08:00:00 CEST | Pressemelding
INTERXION HOLDING NV (NYSE: INXN), a leading European provider of carrier and cloud-neutral colocation data centre services, today announced that it has signed an agreement with Aqua Comms, the operator of subsea fibre-optic networks interconnecting the United States and Europe, enabling interconnection to the America Europe Connect-2 (AEC-2) subsea cable system from Interxion’s data centre in Copenhagen. AEC-2 is Aqua Comms’s portion of the Havfrue subsea cable project, connecting New Jersey, U.S.A., to Ireland, and Denmark. The America Europe Connect-2 cable is scheduled to land in Blaabjerg, near Esbjerg in September 2019 and will be the first new cable connecting Denmark to the U.S. in nearly two decades. Aqua Comms supplies fibre pairs, spectrum and capacity networking solutions to the global media, content and carrier markets. “The large number of networks and content platforms present at Interxion’s Copenhagen campus makes it an efficient location for AEC-2 to interconnect with
digital.security Introduces the First European Security Label for Connected Solutions21.6.2019 07:00:00 CEST | Pressemelding
digital.security, the leading European certifier for connected object security, has just announced the launch of the IoT Qualified as Secured (IQS) programme – the first certification programme for Internet of Things (IoT) designers who want to have the security of their IoT solutions checked by an independent third party. Designed for users, this label can be used by IoT designers to check the security of systems that use connected objects. It serves as a reliable and independent indicator for future adopters or users, whether they are professionals or private individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190621005018/en/ The programme featuring the IQS pictogram, IoT manufacturers can check the security of their systems that use connected objects. The IQS label can be awarded to companies in all economic sectors for a period of 2 years and is based on a reference framework made up of national and internationa